[go: up one dir, main page]

WO2023107712A1 - β-GLUCANES SOLUBLES POUR L'INDUCTION D'UNE IMMUNITÉ ENTRAÎNÉE - Google Patents

β-GLUCANES SOLUBLES POUR L'INDUCTION D'UNE IMMUNITÉ ENTRAÎNÉE Download PDF

Info

Publication number
WO2023107712A1
WO2023107712A1 PCT/US2022/052436 US2022052436W WO2023107712A1 WO 2023107712 A1 WO2023107712 A1 WO 2023107712A1 US 2022052436 W US2022052436 W US 2022052436W WO 2023107712 A1 WO2023107712 A1 WO 2023107712A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
glucan
soluble
effective amount
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/052436
Other languages
English (en)
Other versions
WO2023107712A8 (fr
Inventor
Nandita BOSE
Xiaohong Qiu
Kathryn BIEGING-ROLETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hibercell Inc
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of WO2023107712A1 publication Critical patent/WO2023107712A1/fr
Publication of WO2023107712A8 publication Critical patent/WO2023107712A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • myeloablative which imparts dose-limiting toxicities and renders the patient vulnerable to secondary clinical conditions, such as bacterial, viral, and fungal infections, which can compromise treatment outcomes.
  • the present disclosure provides methods of treating or preventing various conditions, diseases, or disorders (e.g., cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID- 19, and myeloablation) in a subject in need thereof, the methods generally comprise administering to the subject a therapeutically effective amount of a soluble 0- glucan, wherein administering the soluble 0-glucan induces trained immunity in the subject, thereby treating or preventing the condition, disease, or disorder.
  • the condition, disease or disorder is a cancer described herein.
  • condition, disease, or disorder is associated with a cancer described herein (e.g., sepsis/septicemia, pneumonia, fungal infection, immunoparalysis) and/or the treatment of cancer (e.g., administration of a chemotherapeutic agent and/or radiation therapy).
  • a cancer described herein e.g., sepsis/septicemia, pneumonia, fungal infection, immunoparalysis
  • the treatment of cancer e.g., administration of a chemotherapeutic agent and/or radiation therapy.
  • condition, disease, or disorder is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) infection and/or COVID- 19.
  • SARS-CoV- 2 severe acute respiratory syndrome coronavirus 2
  • the disclosure provides a method of treating sepsis and/or septicemia in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble p-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons (kDa) to about 400 kDa.
  • the present disclosure provides a method of treating pneumonia in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the present disclosure provides a method of treating immunoparalysis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble p-glucan to the subject, wherein the soluble p- glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the present disclosure provides a method of treating a fungal infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the present disclosure provides a method of treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or COVID- 19 in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble p-glucan to the subject.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • the present disclosure provides a method of enhancing myelopoiesis in a subject to be administered a myeloablative therapy, the method comprising administering to the subject prior to the administration of the myeloablative therapy a therapeutically effective amount of a soluble p-glucan. wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the present disclosure provides a method of enhancing myelopoiesis in a subject that has been administered a myeloablative therapy, the method comprising (i) contacting a plurality of hematopoietic stem cells (HSC) and/or a plurality of myeloid progenitor cells from a donor with a therapeutically effective amount of soluble P-glucan, and (ii) administering to the subject a therapeutically effective amount of the plurality of HSCs and/or the plurality of myeloid progenitor cells.
  • HSC hematopoietic stem cells
  • the present disclosure provides a method of inducing trained immunity in a subject with cancer, the method consisting of administering to the subject a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the therapeutically effective amount of soluble P-glucan is administered to the subject at least about one day prior to a first administration of a cancer immunotherapy.
  • FIG. 1 is a heat map showing increased gene expression of glycolysis markers (e.g., 1 - ADPGK, 2 - ALDH1A1, 3 - ALDH2, 4 - ALDOA, 5 - BPGM, 6 - ENO1, 7 - ENO2, 8 - GAPDH, 9 - GPI, 10 - HK1, 11 - HK2, 12 - HK3, 13 - HKDC1, 14 - LDHA, 15 - PCK2, 16 - PFKL, 17 - PFKM, 18 - PGAM1, 19 - PGK1, 20 - PKM, 21 - TPI1) in healthy human volunteer (HHV) subjects three hours post-treatment with Imprime PGG.
  • Each genetic marker is represented by a number, and the genetic markers are numbered in ascending order from the top to the bottom of the heat map.
  • FIG. 2 is a heat map showing increased gene expression of PI3K-AKT-mT0R pathway markers (e g., 1 - AKT1, 2 - AKT1S1, 3 - AKT2, 4 - ATG13, 5 - BNIP3, 6 - BRAF, 7 - CAB39, 8 - CAB39L, 9 - CCNE1, 10 - CDK2, 11 -CLIP1, 12 - CYCS, 13 - DDIT4, 14 - DEPTOR, 15 - EEF2, 16 - EIF4A1, 17 - EIF4B, 18 - EIF4E, 19 - EIF4E2, 20 - EIF4EBP1, 21 - FBXW11, 22 - HRAS, 23 - IKBKB, 24 - IRS1, 25 - MAP2K1, 26 - MAP2K2, 27 - MAPK1, 28 - MAPK3, 29 - MAPKAP1, 30 - MLST8, 31 - MTOR, 32
  • FIG. 3 is a heat map showing increased gene expression of IL- 1 pathway markers (e.g., 1 - CASP1, 2 - GBP5, 3 - IL18, 4 - IL1B, 5 - IL1R1, 6 - IRAKI, 7 - NFKB1, 8 - NFKBIB, 9 - NFKBIZ, 10 - P2RX7, 11 - PANXI, 12 - TAB1, 13 - TAB2) in HHV subjects three hours post treatment with Imprime PGG.
  • IL- 1 pathway markers e.g., 1 - CASP1, 2 - GBP5, 3 - IL18, 4 - IL1B, 5 - IL1R1, 6 - IRAKI, 7 - NFKB1, 8 - NFKBIB, 9 - NFKBIZ, 10 - P2RX7, 11 - PANXI, 12 - TAB1, 13 - TAB2
  • Each genetic marker is represented by
  • FIG. 4 is a histogram showing an increase in the activation of various transcription factors in human monocytes treated for 12 hours with low binder serum, Imprime PGG 25 pg/mL, and supplemental anti-0-glucan antibody (ABA; 100 pg/mL) compared to monocytes treated for 12 hours with low binder serum and 25 pg/mL Imprime PGG without supplemental ABA.
  • ABA supplemental anti-0-glucan antibody
  • FIG. 5 is a plot showing an increase in H3K4Me3 on IL-1B in a healthy human volunteer subject seven days post-administration of Imprime PGG, as compared to pre-dose levels.
  • the present disclosure provides methods of treating or preventing conditions, diseases, or disorders including, but not limited to, cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID- 19, and myeloablation in a subject by administering to the subject a therapeutically effective amount of a soluble 0-glucan.
  • Administering a soluble 0-glucan described herein to the subject induces trained immunity, thereby treating or preventing the condition, disease, or disorder.
  • compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
  • variable or parameters are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges.
  • an integer in the range of 0 to 40 is specifically intended to individually disclose 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40
  • an integer in the range of 1 to 20 is specifically intended to individually disclose 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
  • composition or “pharmaceutical formulation” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • carrier refers to a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent such a soluble P-glucan, or a pharmaceutically acceptable salt thereof, from one organ, or portion of the body, to another organ, or portion of the body.
  • pharmaceutically acceptable excipient refers to a substance that aids the administration of an active agent to and/or absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient.
  • Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, such as a phosphate buffered saline solution, emulsions (e.g., such as an oil/water or water/oil emulsions), lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer’s solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non- human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
  • the subject is a human.
  • the subject is a non-human animal.
  • solid dosage form means a pharmaceutical dose(s) in solid form, e.g., tablets, capsules, granules, powders, sachets, reconstitutable powders, dry powder inhalers and chewable s.
  • administering means oral administration, administration as a suppository, topical contact, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intralesional administration, intrathecal administration, intracranial administration, intranasal administration or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, ortransdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • co-administer it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g., anti -cancer agent, chemotherapeutic, or treatment for a neurodegenerative disease).
  • a soluble -glucan, or a pharmaceutically acceptable salt thereof can be administered alone or can be co-administered to the patient.
  • Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent).
  • the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
  • an “effective amount” or “therapeutically effective amount” of a compound refers to an amount sufficient to elicit the desired biological response, e.g., to treat a condition, disease, or disorder described herein (e.g., cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID-19, and/or myeloablation).
  • a condition, disease, or disorder described herein e.g., cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID-19, and/or myeloablation.
  • the effective amount of a compound of the disclosure may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject
  • immunoparalysis refers to a state of immunosuppression.
  • the immune system becomes desensitized to an antigen, e.g., an antigen associated with an infection, e.g., lipopolysaccharide.
  • immunoparalysis may be mediated by epigenetic changes, e.g., in monocytes.
  • immunoparalysis occurs as a result of an infection, e.g., sepsis and/or septicemia.
  • the term “late-stage cancer” refers to a stage II cancer, stage III cancer, and/or stage IV cancer, or to any cancer that has metastasized. It will be appreciated that the “late-stage” nature of the cancer disease states can be determined by a physician.
  • myelopoiesis refers to the production of myeloid cells (i.e., cells of the myeloid lineage, e.g., myeloid progenitor cells, granulocytes, monocytes, macrophages, and dendritic cells).
  • hematopoiesis refers to the formation of cellular components of the blood, derived from hematopoietic stem cells. These stem cells reside in the medulla of the bone marrow and have the unique ability to give rise to all the different mature blood cell types.
  • myeloablative therapy refers to a therapy that kills or reduces activity or viability of myeloid cells in the bone marrow of a subject.
  • myeloablative therapies are not limited to therapies that kill all myeloid cells in the bone marrow of a subject; myeloablative therapies may also refer to therapies that kill or reduce viability/activity of a portion of the myeloid cells in the bone marrow of a subject.
  • a myeloablative therapy is a low dose of radiation and/or a low dose of chemotherapy.
  • a myeloablative therapy may comprise a combination of different therapies which are myeloablative individually and/or in combination, e.g., a combination of radiation and a chemotherapeutic agent.
  • the term “trained immunity” refers to a state of secondary enhanced responsiveness, including increased cytokine excretion mediated by metabolic and epigenetic alterations, to re-stimulation after a primary stimulation of myeloid cells and/or their progenitors and stem cells in the bone marrow, spleen and blood.
  • Trained immunity also called innate immune memory
  • innate immune memory is also characterized by increased responsiveness (e.g., high cytokine production) after re-stimulation with a secondary stimulus of myeloid innate immune cells, being induced by a primary stimulation of these cells or their progenitors and stem cells in the bone marrow and spleen, and mediated by epigenetic, metabolic and transcriptional alterations.
  • the skilled practitioner will appreciate that the re -stimulation need not be of the same type as the primary stimulation.
  • Induction of trained immunity can be used to enhance treatment of, e.g., an infection or cancer.
  • P-glucans are polymers of glucose that may be derived from a variety of microbiological and plant sources including, but not limited to, yeast, bacteria, algae, seaweed, mushroom, oats, and barley.
  • Yeast P-glucans have immunomodulatory properties.
  • Yeast P-glucans can occur in various forms including, but not limited to, intact yeast, zymosan, purified whole glucan particles, solubilized zymosan polysaccharide, or highly-purified soluble P-glucans of different molecular weights.
  • yeast p-glucans may be composed of glucose monomers organized as a p-(l,3)-linked glucopyranose backbone with periodic p ⁇ ( 1,3) glucopyranose branches linked to the backbone via p ⁇ ( 1,6) glycosidic linkages.
  • the different forms of yeast p- glucans may exhibit differing properties (e.g., physicochemical and biochemical properties).
  • the mechanism by which yeast p-glucans exert their immunomodulatory effects can be influenced by the structural differences between different forms of the P-glucans including, but not limited to, its particulate or soluble nature, tertiary conformation, length of the main chain, length of the side chain, and frequency of the side chains.
  • the immune stimulating functions of yeast P-glucans are also dependent upon the receptors engaged in different cell types in different species, which again, can be dependent on the structural properties of the P-glucans.
  • P-glucan immunotherapies can include administering to a subject any suitable form of p-glucan or any combination of two or more forms of p-glucan.
  • Suitable p-glucans and the preparation of suitable P-glucans from their natural sources are described in, for example, U.S. Patent No. 9,610,303, which is incorporated herein by reference in its entirety.
  • the p-glucan is derived from a yeast such as, for example, Saccharomyces cerevisiae. (see below).
  • P-glucan is a PAMP (pathogen-associated molecular pattern) capable of triggering innate immune cell function leading to a cascade of immune activation and enhanced anti-tumor killing.
  • the P-glucan is a soluble P-glucan.
  • the average molecular weight of the soluble p-glucan is about 50 to about 500 kDa, about 75 to about 500 kDa, about 100 to about 500 kDa, about 125 to about 500 kDa, about 150 to about 500 kDa, about 175 to about 500 kDa, about 200 to about 500 kDa, about 225 to about 500 kDa, about 250 to about 500 kDa, about 275 to about 500 kDa, about 300 to about 500 kDa, about 325 to about 500 kDa, about 350 to about 500 kDa, about 375 to about 500 kDa, about 400 to about 500 kDa, about 425 to about 500 kDa, about 450 to about 500 kDa, about 475 to about 500 kDa, about 50 to about 475 kDa, about 50 to about 450 kDa, about 50 to about 425 kDa, about 50 to about 400 kD
  • the soluble 0-glucan has an average molecular weight of about 110 to about 175 kDa, about 115 to about 175 kDa, about 120 to about 175 kDa, about 125 to about 175 kDa, about 130 to about 175 kDa, about 135 to about 175 kDa, about 140 to about 175 kDa, about 145 to about 175 kDa, about 150 to about 175 kDa, about 155 to about 175 kDa, about 160 to about 175 kDa, about 165 to about 175 kDa, about 170 to about 175 kDa, about 110 to about 170 kDa, about 110 to about 165 kDa, about 110 to about 160 kDa, about 110 to about 155 kDa, about 110 to about 150 kDa, about 110 to about 145 kDa, about 110 to about 140 kDa, about 110 to about 135
  • the soluble p-glucan has an average molecular weight of about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about
  • the soluble P-glucan has an average molecular weight of about 110 kDa, about 115 kDa, about 120 kDa, about 125 kDa, about 130 kDa, about 135 kDa, about 140 kDa, about 145 kDa, about 150 kDa, about 155 kDa, about 160 kDa, about 165 kDa, about 170 kDa, or about 175 kDa.
  • the soluble p-glucan has an average molecular weight of at least about 110 kDa, at least about 115 kDa, at least about 120 kDa, at least about 125 kDa, at least about 130 kDa, at least about 135 kDa, at least about 140 kDa, at least about 145 kDa, at least about 150 kDa, at least about 155 kDa, at least about 160 kDa, at least about 165 kDa, at least about 170 kDa, or at least about 175 kDa.
  • the aqueous solubility of the soluble p-glucan is at least 10 mg/mL, at least 20 mg/mL, at least 30 mg/mL, at least 40 mg/mL, at least 50 mg/mL, at least 60 mg/mL, at least 70 mg/mL, at last 80 mg/mL, at least 90 mg/mL, or at least 100 mg/mL.
  • the p-glucan may be or be derived from P(l,6)-[poly-(l,3)-D- glucopyranosyl]-poly-P(l,3)-D-glucopyranose, which may also be referred to herein as PGG (IMPRIME PGG, Biothera, Eagan, MN) or Odetiglucan, a highly purified and well characterized form of soluble yeast-derived P-glucan.
  • PGG IrIME PGG, Biothera, Eagan, MN
  • Odetiglucan a highly purified and well characterized form of soluble yeast-derived P-glucan.
  • Imprime PGG has an average molecular weight of about 110 to about 175 kDa, about 115 to about 175 kDa, about 120 to about 175 kDa, about 125 to about 175 kDa, about 130 to about 175 kDa, about 135 to about 175 kDa, about 140 to about 175 kDa, about 145 to about 175 kDa, about 150 to about 175 kDa, about 155 to about 175 kDa, about 160 to about 175 kDa, about 165 to about 175 kDa, about 170 to about 175 kDa, about 110 to about 170 kDa, about 110 to about 165 kDa, about 110 to about 160 kDa, about 110 to about 155 kDa, about 110 to about 150 kDa, about 110 to about 145 kDa, about 110 to about 140 kDa, about 110 to about 135 kD
  • Imprime PGG has an average molecular weight of about 110 kDa, about 115 kDa, about 120 kDa, about 125 kDa, about 130 kDa, about 135 kDa, about 140 kDa, about 145 kDa, about 150 kDa, about 155 kDa, about 160 kDa, about 165 kDa, about 170 kDa, or about 175 kDa.
  • Imprime PGG has an average molecular weight of about 110 kDa to about 175 kDa and an aqueous solubility of at least 100 mg/mL.
  • compositions which comprise a therapeutically effective amount of one or more of the soluble -glucans as described herein, formulated together with one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • compositions containing a soluble P-glucan disclosed herein can be presented in a unit dosage form and can be prepared by any suitable method.
  • a pharmaceutical composition should be formulated to be compatible with its intended route of administration.
  • the pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form will depend upon the intended mode of administration and therapeutic application.
  • compositions described herein are preferably formulated for administration intravenously, such compositions can be administered by other parenteral modes (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection).
  • parenteral administration and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and infrastemal injection and infusion.
  • compositions described herein can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable for stable storage at high concentration.
  • Sterile injectable solutions can be prepared by incorporating an agent described herein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating an agent described herein into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze drying that yield a powder of an agent described herein plus any additional desired ingredient from a previously sterile -filtered solution thereof.
  • the proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • a pharmaceutical formulation that is sterile. Sterilization can be accomplished by any suitable method, e.g., filtration through sterile filtration membranes.
  • filter sterilization can be conducted prior to or following lyophilization and reconstitution.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
  • systemic administration means the administration of a 0- glucan, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • the soluble 0-glucans of the present disclosure which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient (e.g., a soluble 0- glucan described herein) which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular 0-glucan of the present disclosure employed, or the ester, salt, or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular 0-glucan being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular 0- glucan employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the soluble 0-glucans of the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a soluble 0-glucan of the disclosure will be that amount of the soluble 0-glucan which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. When the soluble 0-glucans described herein are co-administered with another agent, the effective amount may be less than when the agent is used alone.
  • the effective daily dose of the soluble 0-glucan may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
  • the disclosure further provides a unit dosage form (e.g., a solution for intravenous administration) comprising a soluble 0-glucan described herein in a therapeutically effective amount for the treatment of a condition, disease, or disorder described herein.
  • a unit dosage form e.g., a solution for intravenous administration
  • the soluble 0-glucan is Imprime PGG.
  • the soluble 0-glucan is formulated as an aqueous solution.
  • the concentration of soluble 0-glucan in the aqueous solution is about 1 to about 10 mg/mL, about 2 to about 10 mg/mL, about 3 to about 10 mg/mL, about 4 to about 10 mg/mL, about 5 to about 10 mg/mL, about 6 to about 10 mg/mL, about 7 to about 10 mg/mL, about 8 to about 10 mg/mL, about 9 to about 10 mg/mL, about 1 to about 9 mg/mL, about 1 to about 8 mg/mL, about 1 to about 7 mg/mL, about 1 to about 6 mg/mL, about 1 to about 5 mg/mL, about 1 to about 4 mg/mL, about 1 to about 3 mg/mL, about 1 to about 2 mg/mL, about 0.2 to about 2 mg/mL, about 0.4 to about 2 mg/mL, about 0.6 to about 2 mg/mL, about 0.8
  • the concentration of soluble P-glucan in the solution is about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 11 mg/mL, about 12 mg/mL, about 13 mg/mL, about 14 mg/mL, about 15 mg/mL, about 16 mg/mL, about 17 mg/mL, about 18 mg/mL, about 19 mg/mL, or about 20 mg/mL.
  • the pH of the solution is about 5.9 to about 6.9, about 6.0 to about 6.9, about 6.1 to about 6.9, about 6.2 to about 6.9, about 6.3 to about 6.9, about 6.4 to about 6.9, about 6.5 to about 6.9, about 6.6 to about 6.9, about 6.7 to about 6.9, about 6.8 to about 6.9, about 6.0 to about 6.8, about 6.1 to about 6.7 about 6.2 to about 6.6, about 6.3 to about 6.5, about 5.95 to about 6.85, about 6.05 to about 6.75, about 6.15 to about 6.65, about 6.25 to about 6.55, or about 6.35 to about 6.55.
  • the pH of the solution is about 5.95, about 6.0, about 6.05, about 6.1, about 6.15, about 6.2, about 6.25, about 6.3, about 6.35, about 6.4, about 6.45, about 6.5, about 6.55, about 6.6, about 6.75, about 6.7, or about 6.75.
  • the osmolality of the solution is about 260 to about 320 mOsmol/kg, about 265 to about 320 mOsmol/kg, about 270 to about 320 mOsmol/kg, about 275 to about 320 mOsmol/kg, about 280 to about 320 mOsmol/kg, about 285 to about 320 mOsmol/kg, about 290 to about 320 mOsmol/kg, about 295 to about 320 mOsmol/kg, about 300 to about 320 mOsmol/kg, about 305 to about 320 mOsmol/kg, about 310 to about 320 mOsmol/kg, about 315 to about 320 mOsmol/kg, about 260 to about 315 mOsmol/kg, about 260 to about 310 mOsmol/kg, about 260 to about 305 mOsmol/kg, about 260 to about 300 mOsmol/kg,
  • the osmolality of the solution is about 260 mOsmol/kg, about 265 mOsmol/kg, about 270 mOsmol/kg, about 275 mOsmol/kg, about 280 mOsmol/kg, about 285 mOsmol/kg, about 290 mOsmol/kg, about 295 mOsmol/kg, about 300 mOsmol/kg, about 305 mOsmol/kg, about 310 mOsmol/kg, about 315 mOsmol/kg, or about 320 mOsmol/kg.
  • Disclosed herein are methods of treating and/or preventing various conditions in a subject in need thereof comprising or consisting of administering a therapeutically effective amount of a soluble P-glucan described herein or a pharmaceutical composition described herein.
  • Said conditions, diseases, or disorders include, but are not limited to, cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID- 19, and myeloablation.
  • methods of treating cancer in a subject in need thereof generally comprise administering to the subject a therapeutically effective amount of a soluble P-glucan.
  • cancer refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, melanomas, etc., including, solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, liver cancer, including hepatocarcinoma, lymphoma, including B -acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), and/or multiple myeloma.
  • cancer refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, melanomas, etc., including
  • cancer refers to lung cancer, breast cancer, ovarian cancer, leukemia, lymphoma, melanoma, pancreatic cancer, sarcoma, bladder cancer, bone cancer, brain cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, liver cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, prostate cancer, metastatic cancer, or carcinoma.
  • cancer refers to all types of cancer, neoplasm, or malignant tumors found in mammals, including leukemia, lymphoma, carcinomas, and sarcomas.
  • Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma, sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., ER positive, ER negative, chemotherapy resistant, Herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, or melanoma.
  • Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head and neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer,
  • leukemia refers broadly to progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
  • Exemplary leukemias that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairycell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leuk
  • sarcoma generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • Sarcomas that may be treated with a compound, pharmaceutical composition, or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abernethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial
  • melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
  • Melanomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infdtrate the surrounding tissues and give rise to metastases.
  • exemplary carcinomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, ductal carcinoma, carcinoma durum
  • certain methods herein treat cancer by decreasing or reducing or preventing the occurrence, growth, metastasis, or progression of a cancer.
  • the methods described herein may be used to treat a cancer by decreasing or eliminating a symptom of a cancer.
  • the P-glucans and/or pharmaceutical compositions disclosed herein may be used as a single agent in a composition or in combination with another agent in a composition to treat a cancer described herein.
  • methods of inducing trained immunity in a subject with a cancer generally comprise administering to the subject a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient.
  • kits for inducing trained immunity in a subject with cancer consisting of administering to the subject a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient.
  • the therapeutically effective amount of soluble p-glucan is administered to the subject at least about one day prior to a first administration of a cancer immunotherapy.
  • kits for inducing trained immunity in a subject with cancer comprising administering to the subject a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the therapeutically effective amount of soluble P-glucan is administered to the subject at least about one day prior to a first administration of a cancer immunotherapy.
  • soluble P-glucan is a soluble P-glucan described herein.
  • the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the composition for use in cancer immunotherapy comprises a checkpoint inhibitor.
  • the checkpoint inhibitor is selected from the group consisting of a PD-1 (programmed cell death protein 1) antagonist, a PD-L1 (programmed cell death protein ligand 1) antagonist, a PD-L2 antagonist, a CD27 (cluster of differentiation 27) antagonist, a CD28 antagonist, a CD70 antagonist, a CD80 antagonist, a CD86 antagonist, a CD 137 antagonist, a CD276 antagonist, a KIRs (killer-cell immunoglobulin-like receptors) antagonist, a LAG3 (lymphocyte-activation gene 3) antagonist, a TNFRSF4 (tumor necrosis factor receptor superfamily, member 4) antagonist, a GITR (glucocorticoid-induced TNFR- related protein) antagonist, a GITRL (GITR ligand) antagonist, a 4-1BBL (4- IBB ligand) antagonist, a CT
  • the checkpoint inhibitor is selected from the group consisting of ipilimumab, tremilimumab, nivolumab, pembrolizumab, pidilizumab, lambrolizumab, BMS- 936559, atezolizumab, and AMP-224, AMP224, AUNP12, BGB108, MCLA134, MEDI0680, PDR001, REGN2810, SHR1210, STIA110X, STIA1110, TSR042, MPDL3280A, MEDI-4736, MSB0010718C, ALN-PDL, BGBA317, KD033, KY1003, STIA100X, STIA1010, STIA1011, STIA1012, STIA101, BMS-663513, and PF-05082566.
  • the checkpoint inhibitor comprises an anti -PD-1 antibody or antigen -binding fragment or derivative thereof.
  • the anti -PD-1 antibody is pembrolizumab.
  • the therapeutically effective amount of soluble P-glucan is administered about 1 hour, about 2 hours, about 3 hour, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days, about 3 weeks, about 4 weeks, about 6 weeks, or about 8 weeks prior to the first administration of the composition for use in cancer immunotherapy.
  • the therapeutically effective amount of soluble p-glucan is administered about 7 days prior to the first administration of the composition for use in cancer immunotherapy.
  • the subject’s cancer has not metastasized at the time of the first administration of the composition for use in cancer immunotherapy.
  • administration of the therapeutically effective amount of soluble p-glucan to the subject prior to the first administration of the composition for use in cancer immunotherapy decreases the amount of metastatic seeding in the subject below that of a control subject receiving a placebo prior to the first administration of the composition for use in cancer immunotherapy.
  • administration of the therapeutically effective amount of soluble P-glucan to the subject prior to the first administration of the composition for use in cancer immunotherapy decreases the amount of metastatic seeding in the subject below that of a subject not receiving the therapeutically effective amount of soluble P-glucan prior to the first administration of the composition for use in cancer immunotherapy.
  • the subject has not previously received a cancer immunotherapy.
  • the subject has not received a cancer immunotherapy about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 18 months, about 2 years, or about 5 years prior to being administered the therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient.
  • kits for treating and/or preventing sepsis and/or septicemia in a subject in need thereof the methods generally comprising administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • provided herein are methods of treating and/or preventing sepsis and/or septicemia in a subject in need thereof, the method consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • methods of treating and/or preventing sepsis and/or septicemia in a subject in need thereof the method consisting of administering a therapeutically effective amount of a soluble p-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject.
  • the soluble -glucan is a soluble p-glucan described herein.
  • the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating sepsis and/or septicemia in a subject in need thereof comprising administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating sepsis and/or septicemia in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating sepsis and/or septicemia in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble p-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject, wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • a subject described herein in need of treatment or prevention of sepsis and/or septicemia has a cancer described herein.
  • the cancer is latestage cancer.
  • the methods of the disclosure comprise a step of identifying a subject in need of treatment with soluble P-glucan or a composition (e.g., a pharmaceutical composition) comprising soluble P-glucan.
  • the methods of the disclosure comprise a step of identifying or selecting a subject in need of treatment for sepsis.
  • the methods comprise selecting a subject that has sepsis or that has been diagnosed with sepsis.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for sepsis, wherein the subject is at risk for sepsis.
  • the subject at risk for sepsis has an infection.
  • the subject at risk for sepsis has cancer.
  • the subject at risk for sepsis has late-stage cancer.
  • the subject at risk for sepsis has lung cancer.
  • the subject at risk for sepsis has diabetes.
  • the subject at risk for sepsis has pneumonia.
  • the subject at risk of sepsis has bacteremia.
  • the subject at risk of sepsis has a chronic kidney or liver disease.
  • the subject at risk of sepsis has an invasive device, e.g., a catheter.
  • the subject at risk of sepsis has a catheter-associated infection, e.g., a catheter-associated urinary tract infection.
  • the subject at risk of sepsis has been intubated.
  • the subject at risk of sepsis has a wound or a bum.
  • the subject at risk for sepsis is a human that is 65 years or older.
  • the subject at risk for sepsis is an infant or a neonate.
  • the subject at risk for sepsis is in a high-risk environment, e.g., a long-term care facility or an intensive care unit.
  • the subject at risk for sepsis is immunocompromised.
  • the subject at risk for sepsis has not been vaccinated against certain infective agents, e.g., influenza or pneumococcus bacteria.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for sepsis, wherein the subject is exhibiting symptoms or signs of sepsis.
  • the subject has experienced or is experiencing a change in mental status.
  • the subject has experienced or is experiencing labored breathing or abnormally rapid breathing.
  • the subject has experienced or is experiencing a drop in systolic blood pressure.
  • the subject’s systolic blood pressure is less than or equal to about 100 mmHg.
  • the subject is experiencing or has experienced nausea, vomiting, and/or diarrhea.
  • the subject has a fever and/or chills.
  • the methods of the disclose comprise a step of identifying or selecting a subject to be administered treatment for sepsis, wherein the subject is in septic shock or is exhibiting signs of septic shock.
  • the subject for example, in some embodiments, the subject’s systolic blood pressure is less than or equal to about 65 mmHg. In some embodiments, the subject has a high level of lactic acid in their blood.
  • the subject having sepsis or at risk of sepsis has not been exposed to radiation, e.g., radiation therapy.
  • the subject having sepsis or at risk of sepsis has an infection.
  • the infection comprises an infection with Streptococcus agalactaie, Escherichia coli, Klebsiella (spp.), Enterobacter (spp.), Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus (spp.), Enterococcus (spp.), Haemophilus influenzae, Legionella (spp.), Chlamydia pnemoniae, Bacteroides fragilis, Candida (spp.), Clostridium (spp.), Listeria monocytogenes, or Rickettsia.
  • provided herein are methods of treating and/or preventing pneumonia, the method comprising administering a therapeutically effective amount of a soluble -glucan to the subject. In some embodiments, provided herein are methods of treating and/or preventing pneumonia, the method consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • kits for treating and/or preventing pneumonia in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble p-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject.
  • the soluble p-glucan is a soluble p-glucan described herein. In some embodiments, the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating pneumonia in a subject in need thereof comprising administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating pneumonia in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating pneumonia in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject, wherein the soluble 0-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • a subject described herein in need of treatment or prevention of pneumonia has a cancer described herein.
  • the cancer is late-stage cancer.
  • the pneumonia is a result, at least in part, of an infection by a bacteria or virus selected from the group consisting of Nocardia (spp.), Rhodococcus equi, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Acinetohacter haumannii-complex, Alcaligenes/Achromohacter (spp.), Burkholderia (spp.), Citrohacter (spp.), Enterohacter cloacaea, Escherichia coli, Klebsiella pneumonia, Moraxella catarrhalis, Neisseria meningitides, Hemophilus influenza, Proteus (spp.), Pseudomonas (spp.), Stenotrophomonas maltophilia, Serretia marcescensa, Chlamydophyla pneumoniae, Legionella (spp.), and Mycoplasm
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for pneumonia, and administering to the subject a therapeutically effective amount of soluble P-glucan. In some embodiments, the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for pneumonia, wherein the subject has pneumonia or has been diagnosed with pneumonia, and administering to the subject a therapeutically effective amount of soluble - glucan.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for pneumonia, wherein the subject is at risk for developing pneumonia, and administering to the subject a therapeutically effective amount of soluble 0-glucan.
  • the subject at risk of developing pneumonia is immunocompromised.
  • the subject is immunosuppressed.
  • the subject has HIV or AIDS.
  • the subject has received an organ transplant.
  • the subject has received chemotherapy and/or steroids.
  • the subject is intubated.
  • the subject is a human that is 2 years or younger. In some embodiments, the subject is a human that is 65 years or older.
  • the subject is hospitalized. In some embodiments, the subject is in an intensive care unit. In some embodiments, the subject is in a long-term care facility. In some embodiments, the subject is a smoker. In some embodiments, the subject has aspirated food or drink. In some embodiments, the subject is prone to aspirating food or drink.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for pneumonia, wherein the subject is exhibiting signs or symptoms of pneumonia, and administering to the subject a therapeutically effective amount of soluble p-glucan.
  • the subject exhibiting signs or symptoms of pneumonia is experiencing chest pain, which may be worse with deep breathing.
  • the subject has a cough, optionally wherein the cough produces phlegm.
  • the subject has fatigue.
  • the subject has a fever and/or chills.
  • the subject is sweating.
  • the subject has a lower-than-normal body temperature.
  • the subject has nausea, vomiting, and/or diarrhea. In some embodiments, the subject is experiencing shortness of breath. In some embodiments, the subject is breathing rapidly. In some embodiments, the subject has experienced or is experiencing confusion. In some embodiments, the subject has recently had an illness, e.g., influenza.
  • kits for treating or preventing immunoparalysis in a subject in need thereof comprising administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • kits for treating or preventing immunoparalysis in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble p-glucan to the subject.
  • kits for treating or preventing immunoparalysis in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject.
  • the soluble P-glucan is a soluble P-glucan described herein. In some embodiments, the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • provided herein are methods of treating or preventing immunoparalysis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a soluble p-glucan to the subject, wherein the soluble p- glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • methods of treating or preventing immunoparalysis in a subject in need thereof the method consisting of administering a therapeutically effective amount of a soluble 0-glucan to the subject, wherein the soluble 0- glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • provided herein are methods of treating or preventing immunoparalysis in a subject in need thereof, the method consisting of administering a therapeutically effective amount of a soluble 0-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject, wherein the soluble 0-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • a subject described herein in need of treatment or prevention of immunoparalysis has a cancer described herein.
  • the cancer is late-stage cancer.
  • a subject described herein in need of treatment or prevention of immunoparalysis has sepsis and/or septicemia.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for immunoparalysis, and administering to the subject a therapeutically effective amount of soluble 0-glucan.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for immunoparalysis, wherein the subject is exhibiting a sign or symptom of immunoparalysis, and administering to the subject a therapeutically effective amount of soluble 0-glucan.
  • the subject has prolonged sepsis.
  • the subject has severe sepsis.
  • the subject has sepsis and has impaired immune function.
  • the subject has prolonged sepsis.
  • the subject has a monocyte HLA-DR %-positivity level of about 30% or less.
  • a whole blood sample of the subject has a reduced ability to produce pro-inflammatory cytokines (e.g., TNFa) in response to stimulation with LPS ex vivo, as compared an appropriate control, e.g., a whole blood sample from a healthy subject.
  • the whole blood sample from the subject has an ex vivo LPS-induced TNFa response of less than about 200 pg/mL after about 4 hours of incubation at about 37 °C.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for immunoparalysis, wherein the subject is at risk for developing immunoparalysis, and administering to the subject a therapeutically effective amount of soluble P-glucan.
  • the subject at risk of developing immunoparalysis has sepsis, has been diagnosed with sepsis, or is at risk of developing sepsis.
  • the subject has experienced septic shock.
  • the subject has prolonged sepsis.
  • kits for treating or preventing a fungal infection in a subject in need thereof comprising administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • provided herein are methods of treating or preventing a fungal infection in a subject in need thereof, the method consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • kits for treating or preventing a fungal infection in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable carrier, diluent, or excipient to the subject
  • the soluble P-glucan is a soluble P-glucan described herein. In some embodiments, the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the fungal infection comprises an infection with a species of fungus from a genus selected from the group consisting of Aspergillus, Candida, Cryptococcus, Scedosporium, Fusarium, and Trichosporon. In certain embodiments, the fungal infection comprises an infection with a species of fungus from the class Zygomycetes .
  • the fungal infection comprises an infection with a species of fungus selected from the group consisting of Aspergillus fumigatus, Aspergillus flavus, Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gattii, Scedosporium apiospermu, Scedosporium prolificans, Trichosporon asahii, and Trichosporon beigelii,
  • a subject described herein in need of treatment or prevention of a fungal infection has a cancer described herein.
  • the cancer is late-stage cancer.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for a fungal infection, and administering to the subject a therapeutically effective amount of soluble P-glucan. In some embodiments, the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for a fungal infection, wherein the subject has a fungal infection or has been diagnosed with a fungal infection, and administering to the subject a therapeutically effective amount of soluble P-glucan.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for a fungal infection, wherein the subject is exhibiting a sign or symptom of a fungal infection, and administering to the subject a therapeutically effective amount of soluble p-glucan.
  • the methods of the disclosure comprise a step of identifying or selecting a subject to be administered a treatment for a fungal infection, wherein the subject is at risk of developing a fungal infection, and administering to the subject a therapeutically effective amount of soluble P-glucan.
  • the subject at risk of developing a fungal infection is immunocompromised or immunosuppressed.
  • the subject has a catheter.
  • the subject has been treated with broad-spectrum antibiotics.
  • the subject has neutropenia.
  • the subject has HIV or AIDS.
  • the subject is an organ transplant recipient.
  • the subject has cancer.
  • kits for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or COVID- 19 in a subject in need thereof comprising administering a therapeutically effective amount of a soluble p-glucan to the subject.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or COVID- 19 in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or CO VID-19 in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan and a pharmaceutically acceptable diluent, carrier, or excipient to the subject
  • the soluble p-glucan is a soluble p-glucan described herein.
  • the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or COVID- 19 in a subject in need thereof comprising administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • kits for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or COVID- 19 in a subject in need thereof consisting of administering a therapeutically effective amount of a soluble P-glucan to the subject, wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • Myelopoiesis [155] In some embodiments, provided herein are methods of enhancing myelopoiesis in a subject to be administered a myeloablative therapy, the method generally comprising administering to the subject prior to the administration of the myeloablative therapy a therapeutically effective amount of a soluble p-glucan.
  • kits for enhancing myelopoiesis in a subject to be administered a myeloablative therapy consisting of administering to the subject prior to the administration of the myeloablative therapy a therapeutically effective amount of a soluble p-glucan.
  • the soluble P-glucan is a soluble P-glucan described herein. In some embodiments, the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for enhancing myelopoiesis in a subject to be administered a myeloablative therapy comprising administering to the subject prior to the administration of the myeloablative therapy a therapeutically effective amount of a soluble P-glucan, wherein the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • kits for enhancing myelopoiesis in a subject to be administered a myeloablative therapy consisting of administering to the subject prior to the administration of the myeloablative therapy a therapeutically effective amount of a soluble p-glucan, wherein the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • a subject described herein in need of treatment prior to administration of myeloablative therapy has a cancer described herein.
  • the cancer is late -stage cancer.
  • the subject described herein in need of treatment prior to administration of myeloablative therapy is to receive an organ and/or tissue transplant.
  • the organ and/or tissue is selected from the group consisting of liver, kidney, pancreas, heart, lung, intestine, cornea, middle ear, skin, bone, bone marrow, heart valve, and connective tissue.
  • the subject described herein in need of treatment prior to administration of myeloablative therapy is to receive an organ transplant
  • the myeloablative therapy is selected from the group consisting of radiation, total body radiation, total lymphoid radiation, cyclophosphamide, busulfan, carmustine, cytarabine, 6-thioguanine, melphalan, etoposide, thiotepa, fludarabin, and a combination of any of the foregoing.
  • the myeloablative therapy comprises a low dose of chemotherapy and/or a low dose of radiation.
  • the myeloablative therapy does not comprise administration of an immunoglobulin .
  • administration of the myeloablative therapy ablates a fraction of the subject’s bone marrow myeloid cells. In some embodiments, administration of the myeloablative therapy ablates a majority of the subject’s myeloid cells. In some embodiments, the myeloablative therapy ablates about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% of the subject’s myeloid cells.
  • kits for enhancing myelopoiesis in a subject that has been administered a myeloablative therapy comprising (i) contacting a plurality of hematopoietic stem cells (HSC) and/or a plurality of myeloid progenitor cells from a donor with a therapeutically effective amount of soluble p-glucan, and (ii) administering to the subject a therapeutically effective amount of the plurality of HSCs and/or the plurality of myeloid progenitor cells.
  • HSC hematopoietic stem cells
  • myeloid progenitor cells from a donor with a therapeutically effective amount of soluble p-glucan
  • kits for enhancing myelopoiesis in a subject that has been administered a myeloablative therapy consisting of (i) contacting a plurality of hematopoietic stem cells (HSC) and/or a plurality of myeloid progenitor cells from a donor with a therapeutically effective amount of soluble P-glucan, and (ii) administering to the subject a therapeutically effective amount of the plurality of HSCs and/or the plurality of myeloid progenitor cells.
  • HSC hematopoietic stem cells
  • kits for enhancing myelopoiesis in a subject that has been administered a myeloablative therapy consisting of (i) contacting a plurality of hematopoietic stem cells (HSC) and/or a plurality of myeloid progenitor cells from a donor with a therapeutically effective amount of soluble P-glucan, and (ii) administering to the subject a composition comprising a therapeutically effective amount of the plurality of HSCs and/or the plurality of myeloid progenitor cells.
  • HSC hematopoietic stem cells
  • step (i) contacting the plurality of HSCs and/or the plurality of myeloid progenitor cells with the therapeutically effective amount of soluble P-glucan occurs ex vivo.
  • step (i) contacting the plurality of HSCs and/or the plurality of myeloid progenitor cells with the therapeutically effective amount of soluble p-glucan occurs in vivo in the donor, and the contacted plurality of HSCs and/or the contacted myeloid progenitor cells are subsequently removed from the donor.
  • the donor is administered the therapeutically effective amount of soluble P-glucan about 1 hour, about 2 hours, about 3 hour, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about
  • the soluble P-glucan is a soluble P-glucan described herein. In some embodiments, the soluble P-glucan has an average molecular weight of about 110 kilodaltons to about 400 kilodaltons.
  • the myeloablative therapy is selected from the group consisting of radiation, total body radiation, total lymphoid radiation, cyclophosphamide, busulfan, carmustine, cytarabine, 6-thioguanine, melphalan, etoposide, thiotepa, fludarabin, and a combination of any of the foregoing.
  • the myeloablative therapy comprises a low dose of chemotherapy and/or a low dose of radiation.
  • the myeloablative therapy does not comprise administration of an immunoglobulin .
  • administration of the myeloablative therapy ablates a fraction of the myeloid cells in the bone marrow of the subject. In some embodiments, administration of the myeloablative therapy ablates a fraction of the subject’s bone marrow cells. In some embodiments, the myeloablative therapy ablates about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% of the myeloid cells in the bone marrow of the subject.
  • the soluble P-glucan has an average molecular weight of about 175 kilodaltons to about 400 kilodaltons. In certain embodiments, the soluble p-glucan has an average molecular weight of about 110 kilodaltons to about 175 kilodaltons.
  • the soluble p-glucan is isolated from yeast. In certain embodiments, the soluble p-glucan is isolated from .S', cerevisiae.
  • the soluble p-glucan comprises soluble p-1,3/1,6 glucan.
  • the soluble P-glucan comprises P(l,6)-[poly-(l,3)-D-glucopyranosyl]-poly- P(l,3)-D-glucopyranose (Imprime PGG).
  • the soluble P-glucan is administered intravenously.
  • the soluble P-glucan is administered in a dose of about 10 to about 100 mg, about 20 to about 100 mg, about 30 to about 100 mg, about 40 to about 100 mg, about 50 to about 100 mg, about 60 to about 100 mg, about 70 to about 100 mg, about 80 to about 100 mg, about 90 to about 100 mg, about 10 to about 90 mg, about 10 to about 80 mg, about 10 to about 70 mg, about 10 to about 60 mg, about 10 to about 50 mg, about 10 to about 40 mg, about 10 to about 30 mg, about 10 to about 20 mg, about 10 to about 40 mg, about 12 to about 40 mg, about 14 to about 40 mg, about 16 to about 40 mg, about 18 to about 40 mg, about 20 to about 40 mg, about 22 to about 40 mg, about 24 to about 40 mg, about 26 to about 40 mg, about 28 to about 40 mg, about 30 to about 40 mg, about 32 to about 40 mg, about 34 to about 40 mg, about 36 to about 40 mg, about 38 to about 40 mg, about 10 to about 20 mg, about 12
  • the soluble p-glucan is administered in a dose of about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg.
  • the soluble P-glucan is administered in a dose of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, or about 20 mg/kg.
  • the soluble P-glucan is administered in a dose of about 4 mg/kg.
  • the soluble p-glucan is administered at a dose of about 20 mg. In certain embodiments, the soluble p-glucan is administered at a concentration of about 1.0 mg/mL.
  • the serum level of IL-ip in the subject increases following administration of the therapeutically effective amount of the soluble p-glucan.
  • the increase in serum level IL- 1 p is measured about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days after administration of the therapeutically effective amount of the soluble P-glucan to the subject.
  • the increase in serum level IL- 1 p is measured about 7 days after administration of the therapeutically effective amount of the soluble P-glucan to the subject.
  • expression of one or more genes in the PI3K-AKT-mTOR pathway in the subject’s monocytes is increased following administration of the therapeutically effective amount of the soluble P-glucan.
  • the increase in expression of one or more genes in the PI3K-AKT-mTOR pathway in the subject’s monocytes is measured about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, or about 1 month after administration of the effective amount of the soluble p-glucan to the subject.
  • the increase in expression of one or more genes in the PI3K-AKT-mTOR pathway in the subject’s monocytes is measured about 3 hours after administration of the effective amount of the soluble P-glucan to the subject.
  • the therapeutically effective amount of the soluble P-glucan does not comprise particulate (i.e., insoluble) P-glucan.
  • the soluble P-glucan comprises P-glucan material that is at least about 95% soluble. In some embodiments, the soluble P-glucan comprises P-glucan material that is at least about 99% soluble.
  • the subject or the donor prior to administration of the therapeutically effective amount of the soluble P-glucan, is screened to determine the level of serum anti-P- glucan antibody (ABA) in the subject or the donor.
  • ABA serum anti-P- glucan antibody
  • subjects or donors having at least some threshold of serum ABA level e.g., any of the serum ABA levels described herein, e.g., 20 pg/mL
  • the subject or the donor may be administered a substance, composition, or treatment which increases their level of serum ABA prior to, or simultaneously with, administration of the 0-glucan.
  • Such a treatment may enhance the potency or efficacy of the 0-glucan administration.
  • said treatment comprises administration of an intravenous immunoglobulin therapy.
  • the serum ABA in the subject is at least about 10 pg/mL, about 15 pg/mL, about 20 pg/mL, about 25 pg/mL, about 30 pg/mL, about 35 pg/mL, about 40 pg/mL, about 45 pg/mL, about 50 pg/mL, about 55 pg/mL, about 60 pg/mL, about 65 pg/mL , about 70 pg/mL, about 75 pg/mL, or about 80 pg/mL, about 85 pg/mL, about 90 pg/mL, about 95 pg/mL, about 100 pg/mL, about 105 pg/mL, about 110 pg/mL, about 115 pg/mL, about 120 pg/mL, about 125 pg/mL, about 130 pg/mL, about 135 pg/
  • the donor or the subject is administered an intravenous immunoglobulin therapy.
  • administration of the intravenous immunoglobulin therapy increases the level of serum ABA in the donor or the subject.
  • the therapeutically effective amount of the soluble 0-glucan is administered systemically.
  • the subject is a human.
  • administering a therapeutically effective amount of a soluble 0- glucan may be accomplished by administration of a composition (e.g., a pharmaceutical composition) comprising the soluble 0-glucan, as described herein.
  • a composition e.g., a pharmaceutical composition
  • Example 1 Assay to determine the expression of genetic markers associated with glycolysis, the PI3K-AKT-mTOR pathway, and the IL-ip pathway in HHV subjects administered Imprime PGG.
  • Example 2 Assay to determine the level of transcription factors in monocytes treated with Imprime PGG or Imprime PGG + IgG ABA.
  • Monocytes were isolated from whole blood using EasySep Human Monocyte Isolation Kit according to manufacturer instructions (Cat # 19359, StemCell Technologies, Vancouver, BC). Isolated cells were treated with Imprime PGG (25 pg/ml) or Imprime and anti-0-glucan IgG (100 pg/ml), each in the presence of 50% serum, for 12 hours.
  • Nuclear extracts were prepared from isolated monocytes using a Nuclear Extraction kit (SK-0001, Signosis, Inc., Santa Clara, CA), and activation of a panel of transcription factors was measured using a biotinylated probe-based array (TF Activation Profiling Plate Array II, FA- 1002, Signosis, Inc., Santa Clara, CA) according to manufacturer instructions.
  • SK-0001, Signosis, Inc., Santa Clara, CA Nuclear Extraction kit
  • TF Activation Profiling Plate Array II FA- 1002, Signosis, Inc., Santa Clara, CA
  • Example 3 Epigenetic assay using H3K4Me3 to determine levels of transcription at IL-1B in subjects treated with Imprime PGG.
  • PBMCs Peripheral Blood Mononuclear Cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente divulgation concerne des méthodes de traitement ou de prévention de divers états pathologiques, maladies et troubles (par exemple, un cancer, une sepsis/septicémie, une pneumonie, une infection fongique, une immunoparalysie, la COVID-19 et une myéloablation) chez un sujet le nécessitant par l'administration au sujet d'une dose thérapeutiquement efficace d'un β-glucane soluble, le β-glucane soluble induisant une immunité entraînée chez le sujet. En particulier, les méthodes de l'invention sont utiles pour traiter ou prévenir des états pathologiques associés au cancer (par exemple, une sepsis/une septicémie, une pneumonie, une infection fongique, une immunoparalysie) et/ou traiter le cancer (par exemple, par administration d'un agent chimiothérapeutique et/ou d'une radiothérapie).
PCT/US2022/052436 2021-12-10 2022-12-09 β-GLUCANES SOLUBLES POUR L'INDUCTION D'UNE IMMUNITÉ ENTRAÎNÉE Ceased WO2023107712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288411P 2021-12-10 2021-12-10
US63/288,411 2021-12-10

Publications (2)

Publication Number Publication Date
WO2023107712A1 true WO2023107712A1 (fr) 2023-06-15
WO2023107712A8 WO2023107712A8 (fr) 2023-12-28

Family

ID=85037069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/052436 Ceased WO2023107712A1 (fr) 2021-12-10 2022-12-09 β-GLUCANES SOLUBLES POUR L'INDUCTION D'UNE IMMUNITÉ ENTRAÎNÉE

Country Status (1)

Country Link
WO (1) WO2023107712A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137710A1 (fr) * 2023-12-22 2025-06-26 Hibercell, Inc. Méthodes de traitement du cancer à l'aide de combinaisons de modulateurs de gcn2 et de belzutifan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633369A (en) * 1989-09-08 1997-05-27 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US9610303B2 (en) 2006-06-15 2017-04-04 Biothera, Inc. Glucan preparations
EP3354319A1 (fr) * 2011-09-09 2018-08-01 Biothera, Inc. Compositions contenant des bêta-glucanes et procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633369A (en) * 1989-09-08 1997-05-27 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US9610303B2 (en) 2006-06-15 2017-04-04 Biothera, Inc. Glucan preparations
EP3354319A1 (fr) * 2011-09-09 2018-08-01 Biothera, Inc. Compositions contenant des bêta-glucanes et procédés d'utilisation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOSE ET AL., J IMMUNOL, 2019
ELIZABETH D FOX ET AL: "Neutrophils from critically ill septic patients mediate profound loss of endothelial barrier integrity", CRITICAL CARE, BIOMED CENTRAL LTD LONDON, GB, vol. 17, no. 5, 7 October 2013 (2013-10-07), pages R226, XP021167404, ISSN: 1364-8535, DOI: 10.1186/CC13049 *
HURLEY PETER J. ET AL: "Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan", ANTICANCER RESEARCH, vol. 40, no. 3, 1 March 2020 (2020-03-01), GR, pages 1467 - 1473, XP093034743, ISSN: 0250-7005, DOI: 10.21873/anticanres.14090 *
MARTIN: "Remington's Pharmaceutical Sciences", 1975, MACK PUBL. CO.
ONDERDONK ANDREW B ET AL: "Anti-Infective Effect of Poly-13-6-Glucotriosyl- 13-3-Glucopyranose Glucan In Vivo", INFECTION AND IMMUNITY, 1 April 1992 (1992-04-01), pages 1642 - 1647, XP093034095, Retrieved from the Internet <URL:https://journals.asm.org/doi/epdf/10.1128/iai.60.4.1642-1647.1992> [retrieved on 20230323] *
PATCHEN M L ET AL: "IN VITRO AND IN VIVO HEMATOPOIETIC ACTIVITIES OF BETAFECTIN PGG-GLUCAN", EXPERIMENTAL HEMATALOGY, ELSEVIER INC, US, vol. 26, no. 13, 1 December 1998 (1998-12-01), pages 1247 - 1254, XP009052101, ISSN: 0301-472X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137710A1 (fr) * 2023-12-22 2025-06-26 Hibercell, Inc. Méthodes de traitement du cancer à l'aide de combinaisons de modulateurs de gcn2 et de belzutifan

Also Published As

Publication number Publication date
WO2023107712A8 (fr) 2023-12-28

Similar Documents

Publication Publication Date Title
EP1776124B1 (fr) Oligonucleotides immunomodulateurs en association avec des mesures chimiotherapeutiques
US20140086890A1 (en) Compositions and methods for treating hyperproliferative disorders
US10201537B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US8394418B2 (en) Combination preparation of a biological response modifier and an anticancer agent and uses thereof
US20180243436A1 (en) Therapeutic cell internalizing conjugates
US20250099543A1 (en) Compositions and methods for treating inflammation and cancer
KR102433847B1 (ko) Iga 신장병증을 치료하기 위한 진세노사이드 m1의 용도
EP3244910A1 (fr) Anticorps de pénétration cellulaire
WO2023107712A1 (fr) β-GLUCANES SOLUBLES POUR L&#39;INDUCTION D&#39;UNE IMMUNITÉ ENTRAÎNÉE
KR101629560B1 (ko) 부작용이 억제된 암치료용 약학 조성물
KR102343728B1 (ko) 마슬린산을 유효성분으로 포함하는 패혈증 또는 패혈성 쇼크의 예방 또는 치료용 조성물
US20040198819A1 (en) Biological response modifier composition and uses thereof
US20240226214A1 (en) Methods for treating inflammatory and fibrotic diseases and disorders
US20240058279A1 (en) Use of cell turnover factors for increasing tissue regeneration
WO2021096970A1 (fr) Thérapies à base de cellules tueuses naturelles
CA2451674A1 (fr) Composition d&#39;un modificateur de reponse biologique et utilisations de celle-ci
CA2428145A1 (fr) Preparation combinee d&#39;un modificateur de reponse biologique et d&#39;un agent anticancereux et utilisations de cette derniere

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22847332

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22847332

Country of ref document: EP

Kind code of ref document: A1